Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814299 | 0.98 | BCL2L1 (0.31) | BCL2L1BAD | |
| SCHEMBL7154226 | 0.78 | — | — | |
| SCHEMBL953469 | 0.69 | CES1 (0.37) | BCL2L1BAD | |
| SCHEMBL814797 | 0.68 | TSHR (0.36) | BCL2L1BAD | |
| SCHEMBL3026560 | 0.67 | BCL2L1 (0.33) | BCL2L1BAD | |
| SCHEMBL9461283 | 0.66 | BCL2L1 (0.50) | BCL2L1BAD | |
| SCHEMBL550024 | 0.66 | BCHE (0.37) | — | |
| SCHEMBL817176 | 0.65 | TSHR (0.38) | BCL2L1BAD | |
| SCHEMBL11199730 | 0.63 | TSHR (0.39) | BCL2L1BAD | |
| SCHEMBL1278375 | 0.63 | BCL2L1 (0.52) | BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| WO-2019097080-A9 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | KIAKOS KONSTANTINOS (AT) | 2020-10-15 | — | — | WO | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200148646-A1 | 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550088-B2 | 6-substituted and 7-substituted morphinan analogs and the use thereof | PURDUE PHARMA L.P. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3087078-B1 | 7-BETA-ALKYL ANALOGS OF ORVINOLS | PURDUE PHARMA LP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2951160-B1 | BENZOMORPHAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2931729-B1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | PURDUE PHARMA LP (US) | 2019-02-06 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8110602-B2 | Compounds comprising heterocyclic-substituted piperidine for treating pain | PURDUE PHARMA L.P. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2397477-A1 | Heterocyclic-substituted piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110136846-A1 | Buprenorphine Analogs | PURDUE PHARMA L.P. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2280008-A2 | Heterocyclic-substituted piperidines as ORL-1 ligands | Purdue Pharma L.P. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2076506-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | BCL2L1 3317/4885BAD 1142/4885 |
| US-20200148646-A1 | 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF | OPRL1, OPRM1, OPRD1 | BCL2L1 4462/4885BAD 1793/4885 |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | BCL2L1 2458/4885BAD 229/4885 |
| US-10550088-B2 | 6-substituted and 7-substituted morphinan analogs and the use thereof | OPRL1, OPRM1, OPRD1 | BCL2L1 4462/4885BAD 1793/4885 |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | BCL2L1 728/4885BAD 118/4885 |
| US-20110136846-A1 | Buprenorphine Analogs | OPRL1, OPRD1, OPRK1 | BCL2L1 1228/4885BAD 1807/4885 |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | STAT3, JAK2, STAT6 | BCL2L1 728/4885BAD 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.